Literature DB >> 15023363

Viral and cellular kinases are potential antiviral targets and have a central role in varicella zoster virus pathogenesis.

Jennifer F Moffat1, Michelle A McMichael, Stacey A Leisenfelder, Shannon L Taylor.   

Abstract

Herpesviruses utilize viral and cellular kinases for replication, and these mediate essential functions that are important for viral pathogenesis. Elucidating the roles of kinases in herpesvirus infections may highlight virus-host interactions that are possible targets for kinase inhibitors with antiviral activity. Varicella zoster virus (VZV) encodes two kinases that phosphorylate viral proteins involved in regulation, assembly, and virulence. VZV infection also induces the activity of host cell cyclin-dependent kinases (cdk4 and cdk2) in nondividing cells, causing a disregulation of the cell cycle. Roscovitine and Purvalanol, kinase inhibitors that target cdks, prevent VZV replication at concentrations with few cytotoxic effects. Cdk inhibitors therefore have potential as antivirals that may extend to a broad range of viruses and have the added advantage that resistance does not arise easily.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15023363     DOI: 10.1016/j.bbapap.2003.11.026

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  9 in total

1.  Varicella-zoster virus infection of human foreskin fibroblast cells results in atypical cyclin expression and cyclin-dependent kinase activity.

Authors:  Stacey A Leisenfelder; Jennifer F Moffat
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

2.  Compounds that target host cell proteins prevent varicella-zoster virus replication in culture, ex vivo, and in SCID-Hu mice.

Authors:  Jenny Rowe; Rebecca J Greenblatt; Dongmei Liu; Jennifer F Moffat
Journal:  Antiviral Res       Date:  2010-03-20       Impact factor: 5.970

3.  Varicella-zoster virus infection of human fibroblast cells activates the c-Jun N-terminal kinase pathway.

Authors:  Heidi J Zapata; Masako Nakatsugawa; Jennifer F Moffat
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

Review 4.  Potential of protein kinase inhibitors for treating herpesvirus-associated disease.

Authors:  Renfeng Li; S Diane Hayward
Journal:  Trends Microbiol       Date:  2013-04-19       Impact factor: 17.079

5.  Cyclin-dependent kinase 1/cyclin B1 phosphorylates varicella-zoster virus IE62 and is incorporated into virions.

Authors:  Stacey A Leisenfelder; Paul R Kinchington; Jennifer F Moffat
Journal:  J Virol       Date:  2008-09-17       Impact factor: 5.103

6.  Roscovitine inhibits activation of promoters in herpes simplex virus type 1 genomes independently of promoter-specific factors.

Authors:  Prerna Diwan; Jonathan J Lacasse; Luis M Schang
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 7.  Targeting Host Cellular Factors as a Strategy of Therapeutic Intervention for Herpesvirus Infections.

Authors:  Kumari Asha; Neelam Sharma-Walia
Journal:  Front Cell Infect Microbiol       Date:  2021-03-19       Impact factor: 5.293

8.  Regulation of the retinoblastoma proteins by the human herpesviruses.

Authors:  Adam J Hume; Robert F Kalejta
Journal:  Cell Div       Date:  2009-01-15       Impact factor: 5.130

9.  Cell cycle modulation by Marek's disease virus: the tegument protein VP22 triggers S-phase arrest and DNA damage in proliferating cells.

Authors:  Laëtitia Trapp-Fragnet; Djihad Bencherit; Danièle Chabanne-Vautherot; Yves Le Vern; Sylvie Remy; Elisa Boutet-Robinet; Gladys Mirey; Jean-François Vautherot; Caroline Denesvre
Journal:  PLoS One       Date:  2014-06-19       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.